Page last updated: 2024-09-05

lu 135252 and Cardiovascular Diseases

lu 135252 has been researched along with Cardiovascular Diseases in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Amann, K; El-Shakmak, A; Gross, ML; Hansen, A; Heiss, N; Münter, K; Ritz, E; Szabo, A; Weckbach, M1

Other Studies

2 other study(ies) available for lu 135252 and Cardiovascular Diseases

ArticleYear
ACE-inhibition is superior to endothelin A receptor blockade in preventing abnormal capillary supply and fibrosis of the heart in experimental diabetes.
    Diabetologia, 2004, Volume: 47, Issue:2

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Thoracic; Arterioles; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Collagen Type IV; Coronary Vessels; Diabetes Mellitus, Experimental; Endothelin A Receptor Antagonists; Endothelin-1; Fibrosis; Gene Expression; Heart; Immunohistochemistry; In Situ Hybridization; Indoles; Male; Myocardium; Phenylpropionates; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Transforming Growth Factor beta

2004
LU 135252. HMR 4005.
    Drugs in R&D, 1999, Volume: 2, Issue:1

    Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Drugs, Investigational; Endothelin Receptor Antagonists; Phenylpropionates; Pyrimidines; Receptor, Endothelin A

1999